Halogenoderma

Back

Background

Halogenodermas are skin eruptions that result after exposure to halogen-containing drugs or substances. The terms iododerma, bromoderma, and fluoroderma are used to describe skin lesions that occur after an individual consumes iodide-, bromide-, or fluoride-containing preparations. Fluoride-contaminated groundwater runs the risk of cutaneous and visceral adverse effects, a particular concern in Pakistan.[1]

Bromoderma is a cutaneous reaction caused by the use of products containing bromide. The administration of a syrup that contains sodium bromide is one cause.[2] An infant also developed it from a calcium bromide–containing syrup for colic.[3] When cardiac catheterization is performed with iodinated contrast material, vegetating cutaneous nodules can occur.[4]

Pathophysiology

Halogenoderma may represent a delayed hypersensitivity allergic response. In some studies, the results of lymphocyte transformation tests with iodinated human serum albumin have been positive, suggesting that iodine may act as a hapten.

Iodides can increase the movement of polymorphonuclear leukocytes into the areas of inflammation. Inflammatory mediators released from neutrophils might be responsible for the hyperproliferative and vegetative aspects of the skin lesions.[5] Perhaps, in some cases, these mediators may account for the histopathologic changes of leukocytoclastic vasculitis that are sometimes evident.[6]

Etiology

In past years when iodine was used as an expectorant, sedative, anti-inflammatory, and antithyroid agent, iododermas were more common. Nowadays, the administration of iodide-containing radiopaque contrast medium[7, 8] for cholecystography[9] and urography is the most common cause, especially in patients in renal failure. Acute iododerma due to iodinated contrast media has been well described.[10] Iodine I 131 treatment for hyperthyroidism[11] has also been reported to induce iododerma of the ankles and feet in approximately 2% of the treated patients.[12] . Oral potassium iodide for hyperthyroidism may produce an acneiform eruption of the face.[13] It may rarely develop after topical use of iodine following topical povidone-iodine application.[14]  Iododerma may occur from iodinated multivitamins.[15]

Bromoderma develops after an individual consumes bromide-containing drugs.[16, 17] For example, potassium bromide is frequently used as an anticonvulsant drug in the treatment of epilepsy. Bromocriptine is a dopamine agonist used for pituitary adenomas.[18] It has also been used as a sedative. It may produce bromoderma in infants too.[19]

Fluoride gel preparations, applied topically to the teeth, are prophylactically used as effective cariostatic agents in patients receiving radiation therapy.

Patient Education

Patients with iododermas should be instructed to avoid iodine in their diet, medications, and future radiographic studies.

History

Papulonodular eruptions, having an acneiform appearance, may occur after the ingestion of certain bromide and iodide preparations. The eruptions are less common with fluoride ingestion.

Fluoride gel preparations for the prophylaxis of postirradiation dental caries may cause fluorodermas when they are applied to the teeth.[20]

Bromoderma is rare and due to ingestion, inhalation, or contact with products containing bromides.[21]

Physical Examination

Bromoderma tends to be evident as pustules or vegetating plaques; sometimes, plaques with a periphery of pustules appear. In bromoderma, the pustules usually appear on the lower extremities. In iododerma, the pustules are more likely to occur on the face, they appear less papillomatous, and they may become ulcerated.

Iododerma is characterized by vesicular, pustular, hemorrhagic, suppurative, and/or ulcerative lesions that occur on the areas of the skin with the highest concentration of sebaceous glands, such as the face; however, the mucous membranes, the extremities, and the trunk can also be affected.[7] Vegetating iododerma has also been reported to be associated with pulmonary infiltrates.[22] Some patients have had swelling of salivary glands (iodide mumps).[23] Localized pustulosis had been reported after povidone-iodine sitz baths.[24]

Bromoderma is characterized by multiple, vegetative, ulcerating, and pustular lesions with elevated papillomatous borders, especially on the legs. Bromoderma can appear as a follicular eruption on any hair-bearing body surface and can also occur in the butterfly area of the face.

Fluoroderma that develops after the skin is exposed to fluoride-containing preparations resembles iododerma; the papulonodular lesions are numerous and scattered.

Laboratory Studies

Serum or urine bromide and iodide levels should be measured.

Serum immunoelectrophoresis should be performed. Monoclonal gammopathy has been reported in some patients with iododerma and bromoderma.[25] Therefore, serum immunoelectrophoresis should be considered.

Histologic Findings

Cutaneous halogenoderma produces a suggestive pattern of epidermal and dermal changes. Papillomatosis may be observed, sometimes to the level of pseudoepitheliomatous hyperplasia or acanthosis. Often, intraepidermal abscesses form with neutrophils, eosinophils, and, at times, necrotic or even acantholytic keratinocytes within them.[26] These epidermal changes tend to be more pronounced in bromoderma than in iododerma, in which case the epidermis may be more likely to become eroded or ulcerated.

The epidermal and dermal alterations in fluoroderma tend to be milder than those of the other 2 eruptions.

In the dermis, a dense infiltrate of mainly neutrophils and some leukocytoclasia may be initially observed around areas of dermal necrosis. True vasculitis may be present. Eosinophils may also be evident; at times, these may be numerous. Later, the infiltrate becomes more chronic, with a predominance of histocytes that have abundant cytoplasm and large nuclei.

Medical Care

Usually, no specific treatment is required. Halogenoderma resolves 4-6 weeks after the causative factor is eliminated. Diuretics may be used to speed bromide ion clearance. The skin lesions may be treated with corticosteroids.

Diet

Patients with iododermas should avoid iodine in their diet.

Author

Robert A Schwartz, MD, MPH, Professor and Head of Dermatology, Professor of Pathology, Professor of Pediatrics, Professor of Medicine, Rutgers New Jersey Medical School

Disclosure: Nothing to disclose.

Coauthor(s)

Lajos Kemeny, MD, PhD, DSc, Professor and Head, Department of Dermatology and Allergology, Albert Szent-Gyorgyi Medical Center, University of Szeged, Hungary

Disclosure: Nothing to disclose.

Specialty Editors

David F Butler, MD, Former Section Chief of Dermatology, Central Texas Veterans Healthcare System; Professor of Dermatology, Texas A&M University College of Medicine; Founding Chair, Department of Dermatology, Scott and White Clinic

Disclosure: Nothing to disclose.

Jeffrey J Miller, MD, Associate Professor of Dermatology, Pennsylvania State University College of Medicine; Staff Dermatologist, Pennsylvania State Milton S Hershey Medical Center

Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD, Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Disclosure: Nothing to disclose.

Additional Contributors

Neil Shear, MD, Professor and Chief of Dermatology, Professor of Medicine, Pediatrics and Pharmacology, University of Toronto Faculty of Medicine; Head of Dermatology, Sunnybrook Women's College Health Sciences Center and Women's College Hospital, Canada

Disclosure: Nothing to disclose.

References

  1. Rasool A, Farooqi A, Xiao T, Ali W, Noor S, Abiola O, et al. A review of global outlook on fluoride contamination in groundwater with prominence on the Pakistan current situation. Environ Geochem Health. 2017 Dec 19. [View Abstract]
  2. Bel S, Bartralot R, García D, Aparicio G, Castells A. Vegetant bromoderma in an Infant. Pediatr Dermatol. 2001 Jul-Aug. 18(4):336-8. [View Abstract]
  3. Hoefel ID, Camozzato FO, Hagemann LN, Rhoden DL, Kiszewski AE. Bromoderma in an infant. An Bras Dermatol. 2016 Sep-Oct. 91 (5 suppl 1):17-19. [View Abstract]
  4. Miranda-Romero A, Sánchez-Sambucety P, Esquivias Gómez JI, Martínez Fernández M, Bajo del Pozo C, Aragoneses Fraile H, et al. Vegetating iododerma with fatal outcome. Dermatology. 1999. 198(3):295-7. [View Abstract]
  5. Stone OJ. Proliferative iododerma. A possible mechanism. Int J Dermatol. 1985 Nov. 24(9):565-6. [View Abstract]
  6. Vaillant L, Pengloan J, Blanchier D, De Muret A, Lorette G. Iododerma and acute respiratory distress with leucocytoclastic vasculitis following the intravenous injection of contrast medium. Clin Exp Dermatol. 1990 May. 15(3):232-3. [View Abstract]
  7. Rothman LR, Levender MM, Scharf MD, Herman SP, Jabbari A. Iododerma following serial computed tomography scans in a lung cancer patient. J Drugs Dermatol. 2013 May 1. 12(5):574-6. [View Abstract]
  8. Chang MW, Miner JE, Moiin A, Hashimoto K. Iododerma after computed tomographic scan with intravenous radiopaque contrast media. J Am Acad Dermatol. 1997 Jun. 36(6 Pt 1):1014-6. [View Abstract]
  9. Boudoulas O, Siegle RJ, Grimwood RE. Iododerma occurring after orally administered iopanoic acid. Arch Dermatol. 1987 Mar. 123(3):387-8. [View Abstract]
  10. Young AL, Grossman ME. Acute iododerma secondary to iodinated contrast media. Br J Dermatol. 2014 Jun. 170(6):1377-9. [View Abstract]
  11. Wilkin JK, Strobel D. Iododerma occurring during thyroid protection treatment. Cutis. 1985 Oct. 36(4):335-7. [View Abstract]
  12. Paul AK, Al-Nahhas A, Ansari SM, Islam N. Skin eruptions following treatment with Iodine-131 for hyperthyroidism: a rare and un-reported early/intermediate side effect. Nucl Med Rev Cent East Eur. 2005. 8(2):125-7. [View Abstract]
  13. Frankel AJ, Ahmad M, Perl M, Yao J, Pereira F. Acute onset of a vesiculopustular rash in an ICU patient. Dermatol Online J. 2014 Jan 15. 20(1):21249. [View Abstract]
  14. Aliagaoglu C, Turan H, Uslu E, Albayrak H, Yazici S, Kaya E. Iododerma following topical povidone-iodine application. Cutan Ocul Toxicol. 2013 Apr 8. [View Abstract]
  15. Torkamani N, Sinclair R. Iododerma in pregnancy secondary to iodinated multivitamins. Australas J Dermatol. 2015 Aug. 56 (3):235-6. [View Abstract]
  16. Smith SZ, Scheen SR. Bromoderma. Arch Dermatol. 1978 Mar. 114(3):458-9. [View Abstract]
  17. Oda F, Tohyama M, Murakami A, Kanno K, Sonobe N, Sayama K. Bromoderma mimicking pyoderma gangrenosum caused by commercial sedatives. J Dermatol. 2016 May. 43 (5):564-6. [View Abstract]
  18. Maeda S, Kajihara I, Ogata A, Johno T, Jinnin M, Ihn H. Bromoderma in a pituitary adenoma patient treated with bromocriptine. J Dermatol. 2017 May. 44 (5):e95-e96. [View Abstract]
  19. Paloni G, Mattei I, Ravagnan E, Cutrone M. Infantile Bromoderma. J Pediatr. 2013 May 4. [View Abstract]
  20. Blasik LG, Spencer SK. Fluoroderma. Arch Dermatol. 1979 Nov. 115(11):1334-5. [View Abstract]
  21. Pranteda G, Magri F, Muscianese M, D'Arino A, Pranteda G, Fidanza L, et al. A "seasonal bromoderma" in a farmer. Dermatol Ther. 2019 Jan. 32 (1):e12764. [View Abstract]
  22. Pranteda G, Grimaldi M, Salzetta M, Di Molfetta M, Palese E, Panasiti G, et al. Vegetating iododerma and pulmonary eosinophilic infiltration. A simple co-occurrence?. Acta Derm Venereol. 2004. 84(6):480-1. [View Abstract]
  23. Gilgen-Anner Y, Heim M, Ledermann HP, Bircher AJ. Iodide mumps after contrast media imaging: a rare adverse effect to iodine. Ann Allergy Asthma Immunol. 2007 Jul. 99(1):93-8. [View Abstract]
  24. Aydingöz IE, Göktay F, Serdar ZA, Yasar S, Aslan C. Iododerma following sitz bath with povidone-iodine. Australas J Dermatol. 2007 May. 48(2):102-4. [View Abstract]
  25. Cordoliani F, Rybojad M, Morel P, Puissant A. Halogenoderma and monoclonal gammopathy. J Am Acad Dermatol. 1991 Dec. 25(6 Pt 1):1099. [View Abstract]
  26. Rosenberg FR, Einbinder J, Walzer RA, Nelson CT. Vegetating iododerma. An immunologic mechanism. Arch Dermatol. 1972 Jun. 105(6):900-5. [View Abstract]